| Product Code: ETC9951235 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market - Industry Life Cycle |
3.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market - Porter's Five Forces |
3.5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.7 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.8 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume Share, By Symptoms, 2021 & 2031F |
3.9 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume Share, By Dosage, 2021 & 2031F |
3.10 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.11 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in the UK leading to a higher incidence of paraneoplastic neurologic syndrome |
4.2.2 Advancements in medical technology and diagnostic tools improving early detection and treatment of paraneoplastic neurologic syndrome |
4.2.3 Rising awareness among healthcare professionals and patients about paraneoplastic neurologic syndrome and its symptoms |
4.3 Market Restraints |
4.3.1 High treatment costs associated with managing paraneoplastic neurologic syndrome |
4.3.2 Limited availability of specialized healthcare facilities and expertise for diagnosing and treating the syndrome |
5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Trends |
6 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Types |
6.1 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Limbic Encephalitis, 2021- 2031F |
6.1.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Subacute Sensory Neuropathy, 2021- 2031F |
6.1.5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Cerebellar Degeneration, 2021- 2031F |
6.1.6 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Lambert-Eaton Myasthenic Syndrome, 2021- 2031F |
6.1.7 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Peripheral Nerve Hyperexcitability Syndrome, 2021- 2031F |
6.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Treatment |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Medication, 2021- 2031F |
6.2.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Intravenous Immunoglobulin (IVIg), 2021- 2031F |
6.2.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Plasmapheresis, 2021- 2031F |
6.2.5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Physical Therapy, 2021- 2031F |
6.2.6 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Speech Therapy, 2021- 2031F |
6.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Diagnosis |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Blood tests, 2021- 2031F |
6.3.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Lumbar Puncture, 2021- 2031F |
6.3.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Imaging Tests, 2021- 2031F |
6.3.5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Symptoms |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Gait Disturbance, 2021- 2031F |
6.4.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Decreased Muscle Tone, 2021- 2031F |
6.4.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Decreased Speech Intelligibility, 2021- 2031F |
6.4.5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Dysphagia, 2021- 2031F |
6.4.6 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Fine Motor Coordination, 2021- 2031F |
6.4.7 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Visual Problems, 2021- 2031F |
6.4.8 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Dizziness, 2021- 2031F |
6.4.9 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Dizziness, 2021- 2031F |
6.5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Dosage |
6.5.1 Overview and Analysis |
6.5.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Injection, 2021- 2031F |
6.5.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Tablets, 2021- 2031F |
6.5.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Others, 2021- 2031F |
6.6 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Route of Administration |
6.6.1 Overview and Analysis |
6.6.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Oral, 2021- 2031F |
6.6.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.6.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Others, 2021- 2031F |
6.7 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By End-Users |
6.7.1 Overview and Analysis |
6.7.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Clinic, 2021- 2031F |
6.7.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Hospital, 2021- 2031F |
6.7.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By , 2021- 2031F |
6.8 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market, By Distribution Channel |
6.8.1 Overview and Analysis |
6.8.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.8.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.8.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenues & Volume, By , 2021- 2031F |
7 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Export to Major Countries |
7.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Imports from Major Countries |
8 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Key Performance Indicators |
8.1 Average time from symptom onset to diagnosis of paraneoplastic neurologic syndrome |
8.2 Number of clinical trials focused on developing new treatments for the syndrome in the UK |
8.3 Patient satisfaction scores with access to information and support services for paraneoplastic neurologic syndrome |
9 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market - Opportunity Assessment |
9.1 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.3 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.4 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By Symptoms, 2021 & 2031F |
9.5 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By Dosage, 2021 & 2031F |
9.6 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.7 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.7 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market - Competitive Landscape |
10.1 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Paraneoplastic Neurologic Syndrome Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here